F
Francesca Cavallaro
Researcher at Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico
Publications - 18
Citations - 108
Francesca Cavallaro is an academic researcher from Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 4, co-authored 9 publications receiving 29 citations. Previous affiliations of Francesca Cavallaro include University of Milan.
Papers
More filters
Journal ArticleDOI
Viral Infections in HSCT: Detection, Monitoring, Clinical Management, and Immunologic Implications.
Claudio Annaloro,Fabio Serpenti,Giorgia Saporiti,Giulia Galassi,Francesca Cavallaro,Federica Irene Grifoni,Maria Goldaniga,Luca Baldini,Francesco Onida +8 more
TL;DR: The relationship between viral infections and allogeneic hematopoietic stem cell transplantation (HSCT) is still controversial, and almost exclusively regard DNA viruses as discussed by the authors.
Journal ArticleDOI
Low-dose rituximab in autoimmune hemolytic anemia: 10 years after
Bruno Fattizzo,Anna Zaninoni,Loredana Pettine,Francesca Cavallaro,Eros Di Bona,Wilma Barcellini +5 more
TL;DR: Rituximab is becoming the preferred second-line choice for steroid-refractory warm autoimmune hemolytic anemia (wAIHA) and the first-linechoice for cold agglutinin disease (CAD).
Journal ArticleDOI
Recent insights into the role of the microbiome in malignant and benign hematologic diseases.
TL;DR: In this article, a review of studies concerning the impact of microbiome alteration on malignant and benign hematologic disorders beyond stem cell transplant (HSCT) is presented. But most of these studies were focused on hematopoietic stem cell transplants.
Journal ArticleDOI
Infectious Complications in Autoimmune Hemolytic Anemia.
Juri Alessandro Giannotta,Bruno Fattizzo,Bruno Fattizzo,Francesca Cavallaro,Francesca Cavallaro,Wilma Barcellini +5 more
TL;DR: In this paper, the authors collected the available evidence on the frequency and type of infectious complications in AIHA, detailing the risk related to each treatment (i.e., steroids, rituximab, splenectomy, classic immunosuppressive agents, and new target drugs).